相关实验视频

Updated: Sep 9, 2025

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Published on: November 22, 2024

通过基于共识对接的虚拟查研究发现可逆ALDH1A3抑制剂

E Batlle^1,2, R Pequerul², J Farrés²

¹Institute of Cancer Therapeutics, School of Pharmacy and Medical Sciences, Faculty of Life Sciences, University of Bradford, Bradford, BD71DP, UK.

Journal of computer-aided molecular design

|August 31, 2025

概括

研究人员使用计算机辅助药物设计开发了新型脱酶1A3 (ALDH1A3) 抑制剂. 一项虚拟查发现了一种有前途的化合物 (VS1),该化合物作为可逆ALDH1A3抑制剂,为癌症治疗提供了起点.

科学领域:

生物化学和分子生物学
药理学和药物发现
计算化学

背景情况:

脱酶 (ALDHs) 是参与细胞防御和生物过程的关键酶.
ALDH1A亚家族,特别是ALDH1A1和ALDH1A3,与癌症和其他病理生理疾病有关.
针对ALDH1A3代表了各种疾病的潜在治疗策略.

研究的目的:

使用计算机辅助药物设计方法设计和确定脱酶1A3 (ALDH1A3) 的新兴抑制剂.
为潜在的治疗应用发现选择性和强大的ALDH1A3抑制剂.
为ALDH1A3抑制剂的成功优化和成功开发提供起点.

主要方法:

针对ALDH1A3X射线结构的400万种化合物的混合合体和基于结构的虚拟选 (VS).
使用 12 种对接解决方案进行分层和共识对接.
预测ADME属性,结合自由能计算,生物化学选,动力特征和分子动力学 (MD) 模拟.

主要成果:

通过虚拟查和生物化学测试确定一种新的可逆ALDH1A3抑制剂,称为VS1.
分子动力学模拟提供了对蛋白质 - 连接体动力学的见解,与实验结果相关.
VS1 作为进一步基于结构的优化和ALDH1A3 抑制剂的有希望的起点.

结论:

该研究使用全面的计算和实验方法成功发现了一种新型ALDH1A3抑制剂 (VS1).
这些发现支持VS1作为开发针对ALDH1A3的新治疗剂的支架.
预计这项研究将有助于合理设计用于癌症和其他疾病的ALDH抑制剂.

关键词:

一致性对接半氨酸 313/314 MD模拟蛋白质连体的结构动态虚拟选

更多相关视频

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Published on: July 8, 2025

相关概念视频

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...